By Fineline Cube 
China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its J002 to treat dry eye syndrome.
J002: A Promising Therapeutic Biological Product
J002, a Category 1 therapeutic biological product co-developed by Wenzhou Medical University, is currently in the early stages of clinical development. This approval marks a significant step forward in the potential treatment of dry eye syndrome.-Fineline Info & Tech